R&D

  • overview
  • Technologies
  • R&D Pipeline
  • Open Innovation
  • Achivement

OverviewOverview

Samyang Biopharm aims to become a globally recognized research center specialized in DDS (Drug Delivery System) Technology and biodegradable Medical Devices Samyang Biopharm aims to become a globally recognized research center specialized in DDS (Drug Delivery System) Technology and biodegradable Medical Devices

Medicine Medicine

A major focus of research at Samyang Biopharmaceuticals Corp. have been the application of new DDS and innovative drugs applying DDS technologies have successfully been developed. Genexol® PM and Nanoxel® M are two approved cancer drugs that use nano-polymer DDS. Samyang Biopharmaceutical is also the first in the world to succeed in mass producing Pacliaxel, the active pharmaceutical ingredient of Genexol PM and others, through the application of a plant cell culture technology developed internally.

Samyang Biopharmaceutical Corp. has also developed medical patches for the treatment of pain for cancer patients, smoking cessation, and anti-inflammatory analgesia , via the application of TDS (Transdermal Delivery System) technology.

Innovative technologies that effectively deliver biological materials such as RNA, and DNA and virus to selective tissues have been an area of recent focus of research. In addition to drugs based on monoclonal antibody, antibody-drug conjugate and recombinant protein platforms that Samyang Biopharmaceutical is developing, drugs developed with these innovative drug delivery systems are expected to expand new treatment opportunities for cancer patients.

Medical Devices Medical Devices

Trisorb® is the first successful absorbable surgical suture approved in Korea and third world wide developed by Samyang Biopharmaceutical Corp. in 1996. Currently, it is used in approximately 45 countries around the world. Samyang Biopharmaceutical Corp. has also successfully developed Surgisorb®, Monosorb®, Neosorb® and Neosorb® Plus completing the development of a broad suture portfolio. In addition, Biomesh® a periodontal tissue regenerator, and SurgiGuard® a hemostatic agent, are other representative medical devices developed by Samyang Biopharmaceutical Corp.

Samyang Biopharmaceuticals Corp. has been developing wound managing and sealing products that use biodegradable materials, taking advantage of its past successes and experiences in biodegradable material and product manufacture. Additionally Samyang Biopharmaceutical Corp. strives to develop highly functional and high value added medical devices. Development of 3D materials and materials for the application in plastic surgery are some of the efforts. With a long term vision to secure world leading technologies, active research and development in areas such as tissue regeneration and angiology are also being pursued.